Innate inflammation in Parkinson's disease

Cold Spring Harbor Perspectives in Medicine

Volumn 2, Issue 9, 2012, Pages

  Perry, V Hugh ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1, 2, 3, 6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BENZODIAZEPINE RECEPTOR; MINOCYCLINE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXIDOPAMINE; TOXIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; LIPOPOLYSACCHARIDE;

ARTICLE; BRAIN CELL; CELL ACTIVATION; DISEASE ASSOCIATION; DISEASE MODEL; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; META ANALYSIS (TOPIC); MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; SUBSTANTIA NIGRA; T LYMPHOCYTE; TOXICITY; TRANSGENIC ANIMAL; ANIMAL; ENCEPHALITIS; IMMUNOLOGY; MOUSE; NERVE DEGENERATION; NEURITIS; REVIEW;

ANIMALIA;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; DISEASE MODELS, ANIMAL; ENCEPHALITIS; HUMANS; IMMUNITY, INNATE; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MICROGLIA; NERVE DEGENERATION; NEURITIS; PARKINSON DISEASE; T-LYMPHOCYTES; TOXINS, BIOLOGICAL;

EID: 84873278367     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a009373     Document Type: Article

References (83)

1. Aerts MB, Esselink RA, Abdo WF, Bloem BR, Verbeek MM. 2011. CSF α-synuclein does not differentiate between parkinsonian disorders. Neurobiol Aging 33: 430. e1-430. e3.
2. Banati RB, Daniel SE, Blunt SB. 1998. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov Disord 13: 221-27.
3. Barclay AN, Brown MH. 2006. The SIRP family of receptors and immune regulation. Nat Rev Immunol 6: 457-464.
4. Bilbo SD, Schwarz JM. 2009. Early-life programming of later-life brain and behavior: A critical role for the immune system. Front Behav Neurosci 3: 14.
5. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. 2003. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24: 197-211.
6. Brochard V, Combadière B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, Bonduelle O, Alvarez-Fischer D, Callebert J, Launay JM, et al. 2009. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 119: 182-192.
7. Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, HuangD, Kidd G, Dombrowski S, Dutta R, et al. 2006. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci 9: 917-924.
8. Chaudhuri KR, Naidu Y. 2008. Early Parkinson's disease and non-motor issues. J Neurol 255: 33-38.
9. Cunningham C, Wilcockson DC, Campion S, Lunnon K, Perry VH. 2005. Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J Neurosci 25: 9275-9284.
10. Cunningham C, Campion S, Lunnon K, Murray CL, Woods JF, Deacon RM, Rawlins JN, Perry VH. 2009. Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease. Biol Psychiatry 65: 304-312.
11. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. 2009. From inflammation to sickness and depression: When the immune system subjugates the brain. Nat Rev Neurosci 9: 46-56.
12. Dawson TM, Ko HS, Dawson VL. 2010. Genetic animal models of Parkinson's disease. Neuron 66: 646-661.
13. de Haas AH, Boddeke HW, Biber K. 2008. Region-specific expression of immunoregulatory proteins on microglia in the healthy CNS. Glia 56: 888-894.
14. Depino AM, Earl C, Kaczmarczyk E, Ferrari C, Besedovsky H, del Rey A, PitossiFJ, Oertel WH. 2003. Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur J Neurosci 18: 2731-2742.
15. Dickson DW. 2012. Parkinson's disease and parkinsonism: Neuropathology. Cold Spring Harb Perspect Med doi: 10. 1101/cshperspect. a009258.
16. DiPatre PL, Gelman BB. 1997. Microglial cell activation in aging and Alzheimer disease: Partial linkage with neurofibrillary tangle burden in the hippocampus. J Neuropathol Exp Neurol 56: 143-149.
17. Etminan M, Gill S, Samii A. 2003. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: Systematic review and meta-analysis of observational studies. BMJ 327: 128.
18. Field R, Campion S, Warren C, Murray C, Cunningham C. 2010. Systemic challenge with the TLR3 agonist poly I: C induces amplified IFNα/β and IL-1β responses in the diseased brain and exacerbates chronic neurodegeneration. Brain Behav Immun 24: 996-1007.
19. Gagne JJ, Power MC. 2010. Anti-inflammatory drugs and risk of Parkinson disease: A meta-analysis. Neurology 74: 995-1002.
20. Galea I, Bechmann I, Perry VH. 2007. What is immune privilege (not)? Trends Immunol 28: 12-18.
21. Gao HM, Zhang F, Zhou H, Kam W, Wilson B, Hong JS. 2011. Neuroinflammation and a-synuclein dysfunction potentiate each other driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease. Environ Health Perspect 119: 807-814.
22. 11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 21: 404-412.
23. Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, Mehler MF, ConwaySJ, Ng LG, Stanley ER, et al. 2010. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 330: 841-845.
24. Gordon S, Martinez FO. 2010. Alternative activation of macrophages: Mechanism and functions. Immunity 32: 593-604.
25. Gordon S, Taylor PR. 2005. Monocyte and macrophage heterogeneity. Nat Rev Immunol 5: 953-964.
26. Hanisch UK, Kettenmann H. 2007. Microglia: Active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 10: 1387-1394.
27. Herrera AJ, Castano A, Venero JL, Cano J, Machado A. 2000. The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol Dis 7: 429-447.
28. Hirsch EC, Hunot S. 2009. Neuroinflammation in Parkinson's disease: A target for neuroprotection? Lancet Neurol 8: 382-397.
29. Hoek RM, Ruuls SR, Murphy CA, Wright GJ, Goddard R, Zurawski SM, Blom B, Homola ME, Streit WJ, Brown MH, et al. 2000. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 290: 1768-1771.
30. Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, Culliford D, Perry VH. 2009. Systemic inflammation and disease progression in Alzheimer disease. Neurology 73: 768-774.
31. Holmes C, Cunningham C, Zotova E, Culliford D, Perry VH. 2011. Proinflammatory cytokines, sickness behavior, and Alzheimer disease. Neurology 77: 212-218.
32. Hunot S, Boissiere F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y, HirschEC. 1996. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 72: 355-363.
33. International Parkinson Disease Genetics Consortium. 2011. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: A meta-analysis of genome-wide association studies. Lancet 377: 641-649.
34. Kempster PA, Williams DR, Selikhova M, Holton J, Revesz T, Lees AJ. 2007. Patterns of levodopa response in Parkinson's disease: A clinico-pathological study. Brain 130: 2123-2128.
35. Khalif IL, Quigley EM, Konovitch EA, Maximova ID. 2005. Alterations in the colonic flora and intestinal permeability and evidence of immune activation in chronic constipation. Dig Liver Dis 37: 838-849.
36. Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka N, MandelRJ, Bjorklund A. 2002. Parkinson-like neurodegeneration induced by targeted overexpression of α-synuclein in the nigrostriatal system. J Neurosci 22: 2780-2791.
37. Kirik D, Annett LE, Burger C, Muzyczka N, Mandel RJ, Bjorklund A. 2003. Nigrostriatal α-synucleinopathy induced by viral vector-mediated overexpression of human α-synuclein: A new primate model of Parkinson's disease. Proc Natl Acad Sci 100: 2884-2889.
38. Kreutzberg GW. 1996. Microglia: A sensor for pathological events in the CNS. Trends Neurosci 19: 312-318.
39. Lanciego JL, Luquin N, Obeso JA. 2012. Functional neuroanatomy of the basal ganglia. Cold Spring Harb Perspect Med doi: 10. 1101/cshperspect. a009621.
40. Lawson LJ, Perry VH, Dri P, Gordon S. 1990. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 39: 151-170.
41. Lawson LJ, Perry VH, Gordon S. 1992. Turnover of resident microglia in the normal adult mouse brain. Neuroscience 48: 405-415.
42. Lees AJ, Hardy J, Revesz T. 2009. Parkinson's disease. Lancet 373: 2055-2066.
43. Lemstra AW, Groen in't Woud JC, Hoozemans JJ, van Haastert ES, RozemullerAJ, Eikelenboom P, van Gool WA. 2007. Microglia activation in sepsis: A case-control study. J Neuroinflammation 4: 4.
44. Ling Z, Gayle DA, Ma SY, Lipton JW, Tong CW, Hong JS, Carvey PM. 2002. In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain. Mov Disord 17: 116-124.
45. Lunnon K, Teeling JL, Tutt AL, Cragg MS, Glennie MJ, Perry VH. 2011. Systemic inflammation modulates Fc receptor expression on microglia during chronic neurodegeneration. J Immunol 186: 7215-7224.
46. Massano J, Bhatia KP. 2012. Clinical approach to Parkinson's disease: Features, diagnosis, and principles of management. Cold Spring Harb Perspect Med doi: 10. 1101/cshperspect. a008870.
47. McCoy MK, Martinez TN, Ruhn KA, Szymkowski DE, Smith CG, Botterman BR, Tansey KE, Tansey MG. 2006. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J Neurosci 26: 9365-9375.
48. McGeer PL, Itagaki S, Boyes BE, McGeer EG. 1988. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38: 1285-1291.
49. McGeer PL, Schwab C, Parent A, Doudet D. 2003. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine administration. Ann Neurol 54: 599-604.
50. Mittelbronn M, Dietz K, Schluesener HJ, Meyermann R. 2001. Local distribution of microglia in the normal adult human central nervous system differs by up to one order of magnitude. Acta Neuropathol 101: 249-255.
51. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. 1994a. Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 165: 208-210.
52. Mogi M, Harada M, Kondo J, Riederer P, Inagaki H, Minami M, Nagatsu T. 1994b. Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients. Neurosci Lett 180: 147-150.
53. Moseley RL, Hutter-Saunders JA, Stone DK, Gendelman HE. 2012. Inflammation and adaptive immunity in Parkinson's disease. Cold Spring Harb Perspect Med doi: 10. 1101/cshperspect. a009381.
54. Mosser DM, Edwards JP. 2008. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8: 958-969.
55. Nimmerjahn A, Kirchhoff F, Helmchen F. 2005. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308: 1314-1318.
56. Palin K, Cunningham C, Forse P, Perry VH, Platt N. 2008. Systemic inflammation switches the inflammatory cytokine profile in CNS Wallerian degeneration. Neurobiol Dis 30: 19-29.
57. Pavlov VA, Tracey KJ. 2005. The cholinergic anti-inflammatory pathway. Brain Behav Immun 19: 493-499.
58. Pennington S, Snell K, Lee M, Walker R. 2010. The cause of death in idiopathic Parkinson's disease. Parkinsonism Relat Disord 16: 434-437.
59. Perry VH, Gordon S. 1991. Macrophages and the nervous system. Int Rev Cytol 125: 203-244.
60. Perry VH, O'Connor V. 2010. The role of microglia in synaptic stripping and synaptic degeneration: A revised perspective. ASN Neuro 14: e00047.
61. Perry VH, Hume DA, Gordon S. 1985. Immunohistochemical localization of macrophages and microglia in the adult and developing mouse brain. Neuroscience 15: 313-326.
62. Perry VH, Matyszak MK, Fearn S. 1993. Altered antigen expression of microglia in the aged rodent CNS. Glia 7: 60-67.
63. Perry VH, Cunningham C, Holmes C. 2007. Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol 7: 161-167.
64. Pott Godoy MC, Tarelli R, Ferrari CC, Sarchi MI, Pitossi FJ. 2008. Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain 131: 1880-1894.
65. Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, Knapp DJ, Crews FT. 2007. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 55: 453-462.
66. Ransohoff RM. 2007. Microgliosis: The questions shape the answers. Nat Neurosci 10: 1507-1509.
67. Ransohoff RM, Perry VH. 2009. Microglial physiology: Unique stimuli, specialized responses. Annu Rev Immunol 227: 119-145.
68. Sriram K, Miller DB, O'Callaghan JP. 2006. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: Role of tumor necrosis factor-α. J Neurochem 96: 706-718.
69. Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, Micheva KD, Mehalow AK, Huberman AD, Stafford B, et al. 2007. The classical complement cascade mediates CNS synapse elimination. Cell 131: 1164-1178.
70. Stout RD, Jiang C, Matta B, Tietzel I, Watkins SK, Suttles J. 2005. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol 175: 342-349.
71. Stout RD, Watkins SK, Suttles J. 2009. Functional plasticity of macrophages: In situ reprogramming of tumor-associated macrophages. J Leukoc Biol 86: 1105-1109.
72. Streit WJ. 2006. Microglial senescence: Does the brain's immune system have an expiration date? Trends Neurosci 29: 506-510.
73. Su X, Maguire-Zeiss KA, Giuliano R, Prifti L, Venkatesh K, Federoff HJ. 2008. Synuclein activates microglia in a model of Parkinson's disease. Neurobiol Aging 29: 1690-1701.
74. Sugama S, Yang L, Cho BP, DeGiorgio LA, Lorenzl S, Albers DS, Beal MF, VolpeBT, Joh TH. 2003. Age-related microglial activation in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Res 964: 288-294.
75. Teeling JL, Cunningham C, Newman TA, Perry VH. 2010. The effect of non-steroidal anti-inflammatory agents on behavioural changes and cytokine production following systemic inflammation: Implications for a role of COX-1. Brain Behav Immun 24: 409-419.
76. Tremblay ME, Lowery RL, Majewska AK. 2010. Microglial interactions with synapses are modulated by visual experience. PLoS Biol 8: e1000527.
77. Wake H, Moorhouse AJ, Jinno S, Kohsaka S, Nabekura J. 2009. Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. J Neurosci 29: 3974-3980.
78. Walsh S, Finn DP, Dowd E. 2011. Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat. Neuroscience 175: 251-261.
79. Wilms H, Rosenstiel P, Sievers J, Deuschl G, Zecca L, Lucius R. 2003. Activation of microglia by human neuromelanin is NF-κB dependent and involves p38 mitogen-activated protein kinase: Implications for Parkinson's disease. FASEB J 17: 500-502.
80. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H, Przedborski S. 2002. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22: 1763-1771.
81. Wu Z, Zhang J, Nakanishi H. 2005. Leptomeningeal cells activate microglia and astrocytes to induce IL-10 production by releasing pro-inflammatory cytokines during systemic inflammation. J Neuroimmunol 167: 90-98.
82. Wu Z, Tokuda Y, Zhang XW, Nakanishi H. 2008. Age-dependent responses of glial cells and leptomeninges during systemic inflammation. Neurobiol Dis 32: 543-551.
83. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, Wilson B, Zhang W, Zhou Y, Hong JS, et al. 2005. Aggregated α-synuclein activates microglia: A process leading to disease progression in Parkinson's disease. FASEB J 9: 533-542.